Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.75, $0.39 better than the analyst estimate of $2.36. Revenue for the quarter came in at $7.44 billion versus the consensus estimate of $7.29 billion.

"Lilly closed a complex year by delivering impressive results in the fourth quarter of 2020. We finished the year with strong momentum in our core business areas, as volume-based revenue growth for our newest medicines and initial sales of our COVID-19 antibody therapy, coupled with our ongoing productivity agenda, drove robust margin expansion and solid earnings growth," said David A. Ricks, Lilly's chairman and CEO. "I am also encouraged by exciting recent data readouts for three of our most important pipeline assets: tirzepatide, LOXO-305 and donanemab. Each of these potential medicines has a chance to significantly improve patient outcomes in areas of high unmet medical need, and, should they go on to receive approvals, reinforce our growth prospects for the decade ahead."

GUIDANCE:

Eli Lilly & Co. sees FY2021 EPS of $7.75-$8.40, versus the consensus of $8.20. Eli Lilly & Co. sees FY2021 revenue of $26.5-28 billion, versus the consensus of $27.59 billion.

For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.